In October 2010 Mabion SA gained nearly 40 mln PLN funds for the development of MabionCD20. It has been the highest funds obtained by polish company from the beginning of the 1.4-4.1 PO Innovative Economy Programme.
Funds gained will be used until 2014 for the completion of the development of product, making the commercial product manufacture for the world markets. The total value of the project is 74.8 mln PLN.
Currently few other Mabion’s projects regarding development of biotechnological drugs are under review of UE institutions.